A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Clinical trial NCT01287039 · COMPLETED
Trial details
- NCT number
- NCT01287039
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2011-04-01
- Primary completion
- 2013-12-01
- Enrollment
- 489
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.